News

/News

Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

SAN DIEGO, November 14, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, will participate today in a presentation on the development of its two anti-BCMA CAR-T programs: P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate in a Phase 1 clinical trial for the treatment of […]

By |November 14th, 2017|News|Comments Off on Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

SAN DIEGO, November 8, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer will be presented in a poster session at the Society for Immunotherapy of […]

By |November 8th, 2017|News|Comments Off on Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting

SAN DIEGO, November 2, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that three abstracts detailing preclinical data have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. Data will be presented at the 2017 ASH Annual Meeting in Atlanta on December 9th and 10th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/Abstracts/.  

The following abstracts will be presented:
Presentation Title: The […]

By |November 2nd, 2017|News|Comments Off on Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting

Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

SAN DIEGO, Oct. 26, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that the California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to support the clinical development of Poseida’s P-BCMA-101 product candidate. P-BCMA-101 is a chimeric antigen receptor T […]

By |October 26th, 2017|News|Comments Off on Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

SAN DIEGO, October 5th, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene therapy technologies into lifesaving cell therapies, today presented preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer, showing potent anti-tumor activity, a […]

By |October 5th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma

SAN DIEGO, Sept. 26, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, is now enrolling patients in its Phase 1 study of P-BCMA-101, the company’s lead investigational chimeric antigen receptor T cell (CAR-T) immunotherapy for the treatment of multiple myeloma.

“P-BCMA-101 combines a number of […]

By |September 26th, 2017|News|Comments Off on Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma

Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

SAN DIEGO, September 6th, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate for the treatment of multiple myeloma, at the CAR-TCR Summit on T Cell Immunotherapies in Boston.

The presentation, given by Devon […]

By |September 6th, 2017|News|Comments Off on Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

SAN DIEGO, June 5, 2017 – Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data demonstrating the use of the company’s proprietary high-fidelity genome editing system, NextGEN™ CRISPR, for production of allogeneic “universal donor” chimeric antigen receptor  T-cells (CAR-T). In a study presented today […]

By |June 5th, 2017|News|Comments Off on Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) — Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of Teneobio’s UniDabs™, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy. Under the terms of the agreement Poseida […]

By |May 22nd, 2017|News|Comments Off on Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy

Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 4, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the company’s B-cell maturation antigen (BCMA)-specific chimeric antigen receptor CAR T-cell (CAR-T) drug candidate, referred to as P-BCMA-101. Data demonstrated potent and persistent anti-tumor activity, elimination of tumors […]

By |April 4th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting